米拉贝隆治疗膀胱过度活动症.pdf

ORIGINAL PAPER Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies V. W. Nitti,1 V. Khullar,2 P. van Kerrebroeck,3 S. Herschorn,4 J. Cambronero,5 J. C. Angulo,6 M. B. Blauwet,7 C. Dorrepaal,8 E. Siddiqui,9,10 N. E. Martin11 1Department of Urology, NYU SUMMARY What’s known Langone Medical Center, New Introduction: To examine pooled efficacy data from three, large phase III studies • Overactive bladder (OAB) is a chronic condition York, NY, USA 2Urogynaecology Department, comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data that is increasingly prevalent with age and St Mary’s Hospital, Imperial including additional mirabegron 25 mg and tolterodine extended release (ER) represents an increasing healthcare burden to College, London, UK 4 mg results. Methods: This prespecified pooled analysis of three randomised, society. 3Department of Urology, double-blind, placebo-controlled, 12-week studies, evaluated efficacy and safety of • Antimuscarinic drugs are the current mainstay of Maastricht University Medical